샘플 요청 목록

 카트 문의
시장보고서
상품코드
1771079

에리스로포이에틴 자극제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 용도별, 지역별 부문, 경쟁(2020-2030년)

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2020-2030F
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 에리스로포이에틴 자극제 시장은 2024년에 74억 5,000만 달러에 달하며, 2030년까지 CAGR 8.14%로 성장할 것으로 예측됩니다.

에리트로포이에틴 자극제(ESA)는 신장에서 자연적으로 생성되는 당단백질 호르몬인 에리트로포이에틴의 합성 제제로 골수에서 적혈구 생성을 조절하는 역할을 합니다. 이 약제는 만성신장병(CKD), 암 치료, HIV/AIDS, 적혈구 수가 적은 수술 후 빈혈 치료에 널리 사용되고 있습니다. 세계 빈혈 유병률 증가, 특히 임산부, 어린이, 만성질환자 등 취약 계층의 빈혈 증가가 ESA 치료제 수요를 견인하고 있으며, WHO 2025에 따르면 빈혈은 여전히 전 세계에서 중요한 건강 문제이며, 저소득층과 농촌 지역 주민들에게 불균형적으로 영향을 미치고 있습니다. 또한 세계 인구의 고령화는 빈혈에 걸리기 쉬운 상황으로 ESA의 지속적인 사용 확대에 기여할 것으로 예상되며, ESA는 환자의 삶의 질 향상에 중요한 역할을 하며, 빈혈과 관련된 만성 및 급성 질환의 관리에 필수적인 요소로 작용합니다.

시장 개요
예측 기간 2026-2030
시장 규모 : 2024년 74억 5,000만 달러
시장 규모 : 2030년 118억 2,000만 달러
CAGR : 2025-2030년 8.14%
급성장 부문 에포에틴 알파
최대 시장 북미

시장 성장 촉진요인

종양학의 발전

주요 시장 이슈

특허 만료

주요 시장 동향

에포에틴 바이오시밀러로의 전환

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 세계 시장에서 COVID-19의 영향

제5장 고객의 소리

제6장 세계의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별(에포에틴 알파, 에포에틴 베타, 다베포에틴 알파, 기타)
    • 용도별(암, 신장질환, 항레트로바이러스 치료, 신경질환, 기타 용도)
    • 지역별
    • 기업별(2024)
  • 시장 맵

제7장 아시아태평양의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
  • 시장 점유율·예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제8장 유럽의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
  • 시장 점유율·예측
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제9장 북미의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
  • 시장 점유율·예측
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제10장 남미의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
  • 시장 점유율·예측
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제11장 중동 및 아프리카의 에리스로포이에틴 자극제 시장 전망

  • 시장 규모·예측
  • 시장 점유율·예측
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제12장 시장 역학

  • 촉진요인
  • 과제

제13장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 합병과 인수

제14장 세계의 에리스로포이에틴 자극제 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

  • 업계내 경쟁
  • 신규 참여의 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제16장 PESTEL 분석

제17장 경쟁 구도

  • Amgen Inc.
  • Biocon Limited
  • Celltrion Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific
  • LG Lifesciences, Ltd
  • Novartis AG(Sandoz)
  • Panacea Biotec Ltd

제18장 전략적 제안

제19장 조사회사 소개·면책사항

KSA

The Global Erythropoietin Stimulating Agents Market was valued at USD 7.45 billion in 2024 and is projected to grow at a CAGR of 8.14% through 2030. Erythropoietin Stimulating Agents (ESAs) are synthetic forms of erythropoietin, a glycoprotein hormone naturally produced by the kidneys that regulates red blood cell production in the bone marrow. These agents are widely used to treat anemia associated with chronic kidney disease (CKD), cancer therapies, HIV/AIDS, and surgical procedures where red blood cell counts are low. The increasing global prevalence of anemia, especially in vulnerable populations such as pregnant women, children, and individuals with chronic illnesses, is driving demand for ESA therapies. According to WHO 2025, anemia remains a significant global health issue, disproportionately affecting low-income and rural populations. Furthermore, the aging global population, which is more susceptible to conditions leading to anemia, is expected to contribute to sustained growth in ESA usage. ESAs play a crucial role in improving patient quality of life, making them a vital component in managing chronic and acute medical conditions associated with anemia.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.45 Billion
Market Size 2030USD 11.82 Billion
CAGR 2025-20308.14%
Fastest Growing SegmentEpoetin Alfa
Largest MarketNorth America

Key Market Drivers

Advancements in Oncology

The rising incidence of chemotherapy-induced anemia (CIA) has led to a growing reliance on ESAs such as Epoetin Alfa and Darbepoetin Alfa to mitigate fatigue and enhance patient well-being during cancer treatment. Recent advancements in oncology have introduced more effective and targeted therapies, which may reduce the severity of anemia but also require precise supportive treatments like ESAs. Oncology research has also improved the understanding of ESA safety profiles, enabling better identification of patient subgroups that can safely benefit from these therapies. Personalized medicine and oncogenomics have further contributed to tailored ESA administration based on genetic markers and cancer types, optimizing outcomes while minimizing adverse effects. These developments have bolstered ESA integration into oncology protocols, enhancing their clinical utility and market demand.

Key Market Challenges

Patent Expirations

Patent expirations pose a significant challenge to the growth and profitability of the ESA market. As patents for key ESA drugs expire, it paves the way for the introduction of generic and biosimilar versions, intensifying market competition and driving down prices. These lower-cost alternatives often capture a substantial market share, particularly in price-sensitive healthcare systems. While this may improve patient access, it also leads to revenue declines for original ESA manufacturers. The market may become fragmented, with multiple players offering comparable products, increasing pricing pressures and reducing the incentive for continued innovation. Manufacturers are compelled to revise their pricing and market strategies to remain competitive. Although cost savings benefit healthcare systems, the shift can create challenges in ensuring consistent quality, safety, and patient trust in biosimilar products.

Key Market Trends

Shift Toward Epoetin Biosimilars

The emergence and growing acceptance of Epoetin biosimilars are significantly transforming the ESA market landscape. Biosimilars, developed to be highly similar to already approved biologics, offer equivalent safety and efficacy at a lower cost. This price advantage makes biosimilars appealing to healthcare systems and providers aiming to reduce expenditure without compromising treatment quality. The availability of Epoetin biosimilars has increased competition, expanded patient access, and driven broader adoption of ESA therapies, especially in budget-constrained regions. Regulatory approvals from agencies like the FDA and EMA have reinforced confidence in biosimilars, encouraging uptake among physicians and patients. As real-world evidence continues to support their reliability, the shift toward biosimilars is expected to further strengthen, offering substantial cost savings while maintaining treatment standards in managing anemia.

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Erythropoietin Stimulating Agents Market, By Type:

  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa
  • Other Types

Erythropoietin Stimulating Agents Market, By Application:

  • Cancer
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other Applications

Erythropoietin Stimulating Agents Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

Global Erythropoietin Stimulating Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Feed Phytogenic Market

5. Voice of Customer

6. Global Erythropoietin Stimulating Agents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types)
    • 6.2.2. By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications)
    • 6.2.3. By Region
    • 6.2.4. By Company (2024)
  • 6.3. Market Map

7. Asia Pacific Erythropoietin Stimulating Agents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Erythropoietin Stimulating Agents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. India Erythropoietin Stimulating Agents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Australia Erythropoietin Stimulating Agents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Japan Erythropoietin Stimulating Agents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. South Korea Erythropoietin Stimulating Agents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Europe Erythropoietin Stimulating Agents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Erythropoietin Stimulating Agents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany Erythropoietin Stimulating Agents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Spain Erythropoietin Stimulating Agents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy Erythropoietin Stimulating Agents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. United Kingdom Erythropoietin Stimulating Agents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. North America Erythropoietin Stimulating Agents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Erythropoietin Stimulating Agents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Erythropoietin Stimulating Agents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Erythropoietin Stimulating Agents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Erythropoietin Stimulating Agents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Erythropoietin Stimulating Agents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina Erythropoietin Stimulating Agents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia Erythropoietin Stimulating Agents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa Erythropoietin Stimulating Agents Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Erythropoietin Stimulating Agents Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia Erythropoietin Stimulating Agents Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE Erythropoietin Stimulating Agents Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Erythropoietin Stimulating Agents Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Amgen Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (In case of listed companies)
    • 17.1.5. Recent Developments
    • 17.1.6. SWOT Analysis
  • 17.2. Biocon Limited
  • 17.3. Celltrion Inc.
  • 17.4. F. Hoffmann-La Roche Ltd
  • 17.5. Intas Pharmaceuticals Ltd
  • 17.6. Johnson and Johnson
  • 17.7. Pfizer Inc.
  • 17.8. Teva Pharmaceutical Industries Ltd
  • 17.9. Thermo Fisher Scientific
  • 17.10. LG Lifesciences, Ltd
  • 17.11. Novartis AG(Sandoz)
  • 17.12. Panacea Biotec Ltd

18. Strategic Recommendations

19. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제